between methamphetamine (MAP; 1 and 2 mg/kg, s.c.) and scopolamine (SCP; 0.5 and 2 mg/kg, s.c.) was investigated by means of ambulatory activity in mice of the dd strain. The single administration of MAP and SCP increased the ambulatory activity in a dose-dependent manner. The repeated administration of SCP, 5 times at intervals of 3-4 days, elicited a tolerance to its ambulation-increasing effect. The SCP-experienced mice showed no marked change in their sensitivity to the ambulation-increasing effect of MAP. However, when MAP was additionally administered, these mice showed a reverse tolerance to MAP. Such repeated administration of MAP was effective for attenuating the SCP-tolerance.
Methamphetamine
(MAP) and scopol amine (SCP), prototypes of psychomotor stimulant drugs and muscarinic anticholiner gic drugs, respectively, increase ambulatory activity in mice, and the combined adminis tration of the two drugs shows a synergistic action as compared with the ambulation increasing effects of the individual drugs (1) . However, the effects of repeated administra tion of these drugs are different. A reverse tolerance to MAP, but a tolerance to SCP are produced when these drugs are repeatedly administered to mice at intervals of longer than 1 day (2-4). It has been generally con sidered that the ambulation-increasing effect of MAP appears through a stimulant action on central catecholamineraic systems, in particular dopaminergic ones. An indirect stimulation of catecholaminergic systems through a cholinergic blockade is considered to play an important role in the ambulation increasing effect of SCP (5) . It is therefore expected that there is an intimate interaction between MAP and SCP.
It has been emphasized that the reverse tolerance to the ambulation-increasing effect of MAP is closely related with MAP-induced psychotic symptoms (amphetamine psycho sis) in humans (6, 7) , and that the reverse tolerance, once, established, is maintained for a long period (2) . Moreover, it has been reported that various types of drugs produce an enhancement of the sensitivity to metham phetamine (cross reverse tolerance) in animals (8) (9) (10) (11) (12) . We previously reported that a prior SCP experience induced neither a cross reverse tolerance nor tolerance to MAP in mice of the dd strain (13) . However, a dose * To whom all correspondence should be addressed .
related interaction between two drugs has been conducted insufficiently. Hence, the purpose of this experiment was to study the effects of repeated administration of MAP and SCP and the cross interaction between these two drugs by means of am bulatory activity in mice. Furthermore, the effects of repeated administration of MAP and SCP to the SCP-tolerant mice and the mice that showed a reverse tolerance to MAP were also investigated.
Materials and Methods

Animals
The experimental animals used were male mice of the dd strain (Institute of Experimental Animal Research, Gunma University School of Medicine).
Groups of 10 mice had been housed in standard cages (30X20%10 cm) in a controlled room (23=2°C and light period: 6:00-18:00).
These mice had been given a solid diet (MF: Oriental Yeast) and tap water except during the times of the experiment. When the mice were 7 weeks of the age, the experiment was started.
Drugs
The drugs used and the doses administered were methamphetamine HCI (MAP: Dainip pon Pharm.; 1 and 2 mg/kg, s.c.) and scopol amine HBr (SCP: Sigma Chem.; 0.5 and 2 mg/kg, s.c.). These drugs were dissolved in physiological saline vehicle and administered in a fixed volume of 0.1 ml/10 g body weight of mouse regardless of drug doses. Procedure
The apparatus for measuring the ambula tory activity of the mouse was a tilting-type ambulometer with 10 bucket-like plexiglas activity cages of 20 cm in diameter (SMA-10; O'hara & Co.) (14) . Mice were individually put into the activity cages, and after an adaptation period of 30 min, drug adminis tration was carried out. Then, the ambulatory activity of each mouse was measured for 3 hr and 1.5 hr in the cases of MAP and SCP, respectively.
Experiment 1: Mice were divided into 9 groups according to the administration sched ules of drugs (3 doses of MAPx3 doses of SCP). Mice were firstly administered one of 3 doses of MAP (0, saline control; 1 and 2 mg/kg) for 5 times at intervals of 3-4 days.
After the final MAP-administration, these mice were additionally treated with one of 3 doses of SCP (0, 0.5 and 2 mg/kg), 5 times at intervals of 3-4 days. Four days after the final SCP-administration, the mice were again given the same doses of MAP as previously administered.
Experiment 2: The experimental schedule was almost identical with experiment 1 ex cept for the order of the drug administration. Thus, 9 groups of mice were given one of 3 doses of SCP (0, 0.5 and 2 mg/kg), followed by one of 3 doses of MAP, 5 times each, and finally the same doses of SCP as previously administered.
The experiment was carried out between 10:00-17:00.
Statistical analyses
The mean overall ambulatory activity counts for 3 hr after MAP and for 1 .5 hr after SCP were first analyzed using ANOVA. In cases of significant overall variance, com parison between individual mean values was conducted using the paired t-test. When P values were equal to or less than 0.05, they were defined to be significantly different.
Results Figure 1 shows changes in mean overall ambulatory activity counts after the repeated administration of MAP (0, 1 and 2 mg/kg) for 5 times, followed by SCP (0, 0.5 and 2 mg/ kg) for 5 times, and finally the readministra tion of MAP. The activity counts of mice treated with repeated administration of saline for 11 times were much lower throughout the administration regimen. Therefore, these data were excluded from the figure presentation. The 1st administration of MAP increased the mouse's ambulatory activity in a dose dependent manner. The repeated administra tion of MAP induced a reverse tolerance to its ambulation-increasing effect. When SCP was first administered to the mice that showed the reverse tolerance to MAP, they showed higher activity counts than those of the drug-naive and/or saline-treated mice. However, the repeated SCP administration produced a tolerance to its ambulation-increasing effect. The SCP-treatment failed to modify the established reverse tolerance to MAP. Al though the MAP-experienced mice also Fig. 1 . Changes in mean overall ambulatory activity counts for 3 hr after repeated 5 times adminis tration of methamphetamine (MAP: 0, saline vehicle; 1 and 2 mg/kg, s.c.) and those for 1.5 hr after repeated 5 times administration of scopolamine (SCP: 0, saline vehicle; 0.5 and 2 mg/kg, s.c.), and the activity counts for 3 hr after readministration of methamphetamine.
The repeated drug administration regimen was conducted at intervals of 3-4 days, and the readministration of methamphetamine was carried out 4 days after the final scopolamine administration.
The doses of the readministered metham phetamine were the same as those used in the repeated administration regimen. Each closed symbol indicates a significant difference from the value in the 1st administration of methamphetamine and/or scopolamine (P<0.05). *: Significant difference from the value in the saline-treated mice (P<0.05). N =17-2 0. Fig. 2 . Changes in mean overall ambulatory activity counts for 1.5 hr after repeated 5 times admin istration of scopolamine (SCP: 0, saline vehicle; 0.5 and 2 mg/kg, s.c.) and those for 3 hr after repeated 5 times administration of methamphetamine (MAP: 0, saline vehicle; 1 and 2 mg/kg , s.c.) and the activity counts for 1.5 hr after readministration of scopolamine.
The repeated administration regimen was con ducted at intervals of 3-4 days, and the readministration of scopolamine was carried out 4 days after the final methamphetamine administration. The doses of readministered scopolamine were the same as those used in the repeated administration regimen. Each closed symbol indicates a significant difference from the value in the 1st administration of scopolamine and/or methamphetamine (P<0.05). *: Sig nificant difference from the value in the saline-treated mice after the administration of the same dose of scopolamine (P<0.05).
#: Significantly different from the value in the 5th administration of scopolamine or saline within the same group of mice (P<0.05).
N=17-20.
showed a slight increase in the activity in the first administration of saline, they did not show any increase in the activity in the later saline administration. The repeated saline ad ministration elicited no significant change in the MAP reverse tolerance. Figure 2 shows changes in mean overall ambulatory activity counts after the repeated administration of SCP (0, 0.5 and 2 mg/kg) for 5 times, followed by MAP (0, 1 and 2 mg/ kg) for 5 times, and finally the readministra tion of SCP. The 1st administration of SCP increased the mouse's ambulatory activity in a dose-dependent manner. The repeated ad ministration of SCP produced a tolerance to its ambulation-increasing effect. When MAP was administered to the SCP-tolerant mice, they showed no significant change in their sensitivity to the ambulation-increasing effect of MAP as compared with the drug-naive and/ or saline-treated mice. The repeated MAP administration to SCP-tolerant mice produced a reverse tolerance to its ambulation-increas ing effect, and this treatment completely abolished the tolerance to SCP.
Discussion
The present experiment demonstrated that both MAP and SCP increased the ambulatory activity of mice in a dose-dependent manner. However, the ambulation-increasing effects of these drugs changed differently after the repeated administration.
A reverse tolerance to MAP, but tolerance to SCP were induced. These results are in agreement with those re ported previously (2-4), and may reflect dif ferences in the mechanisms of the ambula tion-increasing effect between MAP and SCP. MAP stimulates catecholaminergic systems through an increase in the catecholamine release and an inhibition of the catecholamine reuptake processes (15) . On the other hand, the ambulation-increasing effect of SCP may be produced by an indirect stimulation of the catecholaminergic systems through a block ing of muscarinic-cholinergic systems (5) . The present experiment also demonstrated that the repeated administration of SCP pro duced no marked change in the sensitivity to the ambulation-increasing effect of MAP. This result is consistent with the data previously reported (13) . Therefore, it can be considered that there is no marked induction of cross reverse tolerance from SCP to MAP in the dd strain mice, although the combined adminis tration of MAP and SCP shows a synergistic action on the ambulatory activity (1) .
On the other hand, the repeated MAP ad ministration induced a significant increase in the sensitivity to SCP, showing a cross reverse tolerance from MAP to SCP. Such a cross interaction is similar to those from MAP to morphine (12) and to caffeine (16) . The re peated administration of these two drugs induce neither cross reverse tolerance nor cross tolerance to MAP, whereas the repeated administration of MAP is effective for in ducing a cross reverse tolerance to morphine and caffeine. The ambulation-increasing ef fects of morphine and caffeine are produced by an indirect stimulation of catecholamin ergic systems through an agonistic action on opiate receptors (17) and an antagonistic action on adenosine receptors (18) (19) (20) , respectively. It is therefore considered that the cross reverse tolerance from MAP to SCP, but not from SCP to MAP, are probably due to the difference in the neurochemical properties between MAP and SCP; i.e., SCP stimulates indirectly catecholaminergic systems. How ever, we have not yet completed the neuro chemical study on this topic. Further experi ments are required to elucidate the role of neurochemical mechanisms in the cross interaction between SCP and MAP.
The MAP-experienced mice also demon strated an increased activity when saline was administered, but this activity gradually di minished in the later administration. It is therefore considered that the saline-induced increase in the activity in the MAP-experi enced mice is elicited by conditioning me chanisms, as previously demonstrated (21) .
The present experiment also demonstrated that reverse tolerance to MAP and tolerance to SCP were produced even in the SCP tolerant mice, and the mice that showed the reverse tolerance to MAP, respectively, in dicating that such phenomena appear almost independent of prior drug experience.
However, the repeated administration of MAP, but not saline, to the SCP-tolerant mice was effective for attenuating the SCP tolerance. In contrast, the reverse tolerance to MAP was scarcely modified by the repeated administration of either saline or SCP, clearly showing that MAP-reverse tolerance is ir reversible with cholinergic blockade. Pre viously, we have reported that the MAP reverse tolerance was irreversible with the re peated treatment with antipsychotic drugs (22) and cholinergic drugs (23) . The reverse tolerance to MAP in animals has been con sidered to be related with psychotoxic symp toms induced by MAP-abuse, namely amphet amine psychosis (6, 7) . Considering the results from the present and previous experi ments, in the view points of behavioral phar macology, the psychotoxic effects of am phetamines seem much harder to attenuate once they have been established.
